Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy.

ABSTRACT:

Background and purpose

Generalized myasthenia gravis (gMG) continues to present significant challenges for clinical management due to an unpredictable disease course, frequent disease fluctuations, and varying response to therapy. The recent availability of new pharmacologic therapies presents a valuable opportunity to reevaluate how this disease is classified, assessed, and managed and identify new ways to improve the clinical care of patients with gMG.

Methods

Narrative review was made of publications identified via searches of PubMed and selected congresses (January 2000-September 2022).

Results

New consensus definitions are required to ensure consistency, to better characterize patients, and to identify patients who will benefit from specific drugs and earlier use

SUBMITTER: Sacca F 

PROVIDER: S-EPMC11236062 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature